$271.00 - $271.00
Desmopressin acetate is a synthetic vasopressin analog, commonly abbreviated dDAVP, engineered to favor antidiuretic V2 receptor activity while reducing the pressor profile associated with native arginine vasopressin.
Two structural changes define the molecule: the N-terminal amino group of vasopressin is removed through replacement of Cys1 with a 3-mercaptopropionyl residue, and L-Arg8 is replaced by D-Arg. These modifications alter receptor pharmacology, proteolytic stability and signaling duration while retaining the characteristic cyclic vasopressin-family architecture.
Product Information
| Property | Specification |
|---|---|
| Product Name | Desmopressin Acetate |
| Synonyms | dDAVP; [deamino-Cys1,D-Arg8]-Vasopressin |
| Condensed Sequence | Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH₂ |
| Structural Modification | 1-deamino / 3-mercaptopropionyl at position 1; D-Arg at position 8 |
| Peptide Moiety Formula | C46H64N14O12S2 |
| Peptide Moiety Molecular Weight | Approximately 1069.2 Da |
| Desmopressin CAS | 16679-58-6 |
| Monoacetate CAS | 62288-83-9 |
| Monoacetate Trihydrate CAS | 62357-86-2 |
| Reference Monoacetate Molecular Weight | Approximately 1129.3 Da |
| Reference Monoacetate Trihydrate Molecular Weight | Approximately 1183.3 Da |
| Ring Closure | Disulfide linkage between the N-terminal mercaptopropionyl thiol and Cys6 |
| C-Terminus | Gly-NH₂ |
| Primary Research Target | V2 vasopressin receptor / AVPR2 |
Structural Engineering of Arginine Vasopressin
Desmopressin was designed from the arginine vasopressin scaffold rather than being a simple salt form of the native hormone. Removal of the Cys1 amino functionality and introduction of D-Arg8 substantially change the pharmacological behavior of the cyclic peptide.
The D-Arg substitution also introduces stereochemistry that is absent from endogenous AVP at position 8. Together with the N-terminal deamination, this produces a useful structure–activity model for studying how small changes within vasopressin-family peptides can shift receptor preference and biological persistence.
Preferential V2 Receptor Pharmacology
Desmopressin is widely characterized as a V2-preferential vasopressin receptor agonist. V2 receptors are primarily coupled to Gs, stimulating adenylyl cyclase and increasing intracellular cAMP.
In renal collecting-duct cells, this signaling cascade promotes trafficking of aquaporin-2 water channels toward the apical membrane and provides a well-defined system for investigating receptor-controlled water transport.
Desmopressin is not absolutely exclusive to V2 receptors. Pharmacological studies have also measured agonist activity at V1b, V1a and oxytocin receptors at different affinity ranges. We therefore recommend using receptor-defined systems when subtype selectivity is a critical experimental variable.
Desmopressin and Argipressin Are Chemically Distinct
| Feature | Argipressin | Desmopressin |
|---|---|---|
| Position 1 | Cys with free amino group | 3-Mercaptopropionyl / deamino |
| Position 8 | L-Arg | D-Arg |
| Major Receptor Profile | V1a, V1b and V2 agonist | V2-preferential agonist |
| Common Experimental Focus | Multi-receptor vasopressin biology | V2 signaling and water transport |
Researchers studying the endogenous AVP scaffold can also review Argipressin Acetate if that URL matches the current published product record.
Acetate and Hydration State Matter
The molecular weight of approximately 1069.2 Da refers to the desmopressin peptide moiety. Defined acetate forms have higher formula weights.
Desmopressin monoacetate has a reference molecular weight of approximately 1129.3 Da, while the commonly referenced monoacetate trihydrate has a molecular weight of approximately 1183.3 Da.
We recommend confirming acetate and hydration state from the lot-specific COA before calculating molar concentration. Lyophilized vial mass should not automatically be interpreted as pure desmopressin peptide mass.
Research Applications
Desmopressin acetate can support AVPR2 pharmacology, cAMP assays, aquaporin-2 trafficking studies, epithelial water-transport research and comparative vasopressin analog structure–activity experiments.
Related endocrine peptides can be explored in our Pituitary Hormones collection.
Custom vasopressin analogs, D-amino-acid substitutions and receptor-directed sequence variants can be evaluated through Chemical Peptide Synthesis.
Frequently Asked Questions
What does dDAVP mean?
dDAVP refers to 1-deamino-8-D-arginine vasopressin, the structural description commonly used for Desmopressin.
Is Desmopressin absolutely selective for V2 receptors?
No. It has a strong V2-oriented pharmacological profile, but measurable activity at other vasopressin-family receptors has been reported depending on species and assay conditions.
Does 1069.2 Da include acetate?
No. Approximately 1069.2 Da refers to the desmopressin peptide moiety. Defined acetate and hydrated forms have higher molecular weights.